Key Details
Price
$2.37Annual Revenue
$26.77 MAnnual EPS
-$0.27Annual ROE
-76.93%Beta
0.94Events Calendar
Next earnings date:
Mar 04, 2025Recent quarterly earnings:
Nov 11, 2024Recent annual earnings:
Mar 04, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 04, 2013Analyst ratings
Recent major analysts updates
Screeners with STXS included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL.
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturing of its robotic mapping and guidecatheter for regulatory submissions in Q1 2025. STXS's holistic ecosystem approach, including interventional devices, GenesisX, and digital surgery advancements, aims to solve long-standing issues with robotic adoption in EP.
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of the Genesis RMN ® System by China's National Medical Products Administration (NMPA).
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - TD Cowen Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis Third Quarter 2024 Earnings Conference Call.
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024.
GenesisX was approved in Europe and is set to be approved in the US late this year. The new robot is a giant leap forward in accessibility. Stereotaxis should get MAGiC approved in Europe in October. I expect a US approval no later than Q2 2025. The firm has enough cash to reach breakeven. It won't hire a lot of people right away to sell GenesisX.
FAQ
- What is the primary business of Stereotaxis?
- What is the ticker symbol for Stereotaxis?
- Does Stereotaxis pay dividends?
- What sector is Stereotaxis in?
- What industry is Stereotaxis in?
- What country is Stereotaxis based in?
- When did Stereotaxis go public?
- Is Stereotaxis in the S&P 500?
- Is Stereotaxis in the NASDAQ 100?
- Is Stereotaxis in the Dow Jones?
- When was Stereotaxis's last earnings report?
- When does Stereotaxis report earnings?
- Should I buy Stereotaxis stock now?